BMC Cancer

Table 3 Univariate and multivariate Cox regression analysis of factors associated with overall survival (OS) and disease-free survival (DFS)

From: Analysis of the impact of platinum-based combination chemotherapy in small cell cervical carcinoma: a multicenter retrospective study in Chinese patients

Clinical variable	Overall survival				Disease free survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value	Hazard ratio (95% CI)	P value
Age(years)	0.632 (0.318-1.255)	0.190			0.547 (0.276-1.085)	0.084
≥40 (n = 27, 37.5%)
<40 (n = 45, 62.5%)
Tumor homology	1.717 (0.846-3.485)	0.135			1.681 (0.832-3.396)	0.148
Mixed (n = 22, 30.6%)
Pure (n = 50, 69.4%)
FIGO stage	3.883 (1.936-7.790)	<0.001	3.478 (1.493-9.664)	0.004	3.572 (1.780-7.164)	<0.001	3.104 (1.377-7.978)	0.007
IIa–IV (n = 26, 36.1%)
Ia–Ib2 (n = 46, 63.9%)
Tumor size	2.057 (1.022-4.141)	0.043			2.320 (1.148-4.688)	0.019
>4 cm (n = 27, 37.5%)
≤4 cm (n = 45, 62.5%)
lymphatic metastasis	3.235 (1.642-8.139)	0.009	3.617 (1.441-11.326)	0.006	4.237 (1.792-6.524)	0.005	4.852 (1.613-8.794)	0.014
Positive (n = 42, 58.3%)
Negative (n = 30, 41.7%)
Vascular space invasion	1.923 (0.967-3.824)	0.062			1.529 (0.764-3.059)	0.231
Positive (n = 33, 45.8%)
Negative (n = 39, 54.2%)
Depth of stromal invasion	2.039 (0.908-4.577)	0.084			2.480 (0.1.107-5.559)	0.027
>2/3 (n = 33, 45.8%)
≤2/3 (n = 28, 38.9%)
Chemotherapy	0.227 (0.099-0.524)	0.001	0.264 (0.099-0.671)	0.003	0.223 (0.101-0.496)	<0.001	0.221 (0.091-0.603)	0.006
EP or TP (n = 36, 50.0%)
Others (n = 36, 50.0%)

FIGO, International Federation of Gynecology and Obstetrics; CI, confidence interval; EP, etoposide + cisplatin; TP, paelitaxel + cisplatin; Bold indicates significant values.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com